Aractingi S - Search Results

1

Cutaneous manifestations in SARS-CoV-2 infection (COVID-19): a French experience and a systematic review of the literature.

Matar S, Oulès B, Sohier P, Chosidow O, Beylot-Barry M, Dupin N, Aractingi S. Matar S, et al. Among authors: aractingi s. J Eur Acad Dermatol Venereol. 2020 Nov;34(11):e686-e689. doi: 10.1111/jdv.16775. Epub 2020 Jul 20. J Eur Acad Dermatol Venereol. 2020. PMID: 32589293 Free PMC article. No abstract available.

2

Neutrophilic dermatoses during granulocytopenia.

Aractingi S, Mallet V, Pinquier L, Chosidow O, Vignon-Pennamen MD, Degos L, Dubertret L, Dombret H. Aractingi S, et al. Arch Dermatol. 1995 Oct;131(10):1141-5. Arch Dermatol. 1995. PMID: 7574830

3

[Cutaneous graft versus host disease].

Aractingi S, Chosidow O, Gluckman E, Socié G. Aractingi S, et al. Presse Med. 1995 Apr 8;24(14):679-85. Presse Med. 1995. PMID: 7770416 Review. French.

4

Specific mucosal erosions in hypereosinophilic syndrome. Evidence for eosinophil protein deposition.

Aractingi S, Janin A, Zini JM, Gauthier MS, Chauvenet L, Tobelem G, Prin L, Chosidow O, Frances C. Aractingi S, et al. Arch Dermatol. 1996 May;132(5):535-41. Arch Dermatol. 1996. PMID: 8624150 Review.

5

Cutaneous reactions after treatment with 2-chlorodeoxyadenosine.

Meunier P, Castaigne S, Bastie JN, Chosidow O, Aractingi S. Meunier P, et al. Among authors: aractingi s. Acta Derm Venereol. 1996 Sep;76(5):385-6. doi: 10.2340/0001555576385386. Acta Derm Venereol. 1996. PMID: 8891014 Free article.

6

Cutaneous graft-versus-host disease.

Aractingi S, Chosidow O. Aractingi S, et al. Arch Dermatol. 1998 May;134(5):602-12. doi: 10.1001/archderm.134.5.602. Arch Dermatol. 1998. PMID: 9606330 Review.

7

[Neutrophilic eccrine hidradenitis associated with relapse of acute myeloblastic leukemia].

Saada V, Aractingi S, Leblond V, Marinho E, Frances C, Chosidow O. Saada V, et al. Among authors: aractingi s. Ann Dermatol Venereol. 1998 Jul;125(6-7):420-2. Ann Dermatol Venereol. 1998. PMID: 9747299 French.

8

Prospective evaluation of detoxification pathways as markers of cutaneous adverse reactions to sulphonamides in AIDS.

Wolkenstein P, Loriot MA, Aractingi S, Cabelguenne A, Beaune P, Chosidow O. Wolkenstein P, et al. Among authors: aractingi s. Pharmacogenetics. 2000 Dec;10(9):821-8. doi: 10.1097/00008571-200012000-00007. Pharmacogenetics. 2000. PMID: 11191886

9

Prospective evaluation of risk factors of cutaneous drug reactions to sulfonamides in patients with AIDS.

Eliaszewicz M, Flahault A, Roujeau JC, Fillet AM, Challine D, Mansouri S, Wolkenstein P, Aractingi S, Penso-Assathiany D, Maslo C, Bourgault-Villada I, Chosidow O, Caumes E; Epitox Study Group. Eliaszewicz M, et al. Among authors: aractingi s. J Am Acad Dermatol. 2002 Jul;47(1):40-6. doi: 10.1067/mjd.2002.120468. J Am Acad Dermatol. 2002. PMID: 12077579

10

[Imiquimod and resiquimod. The onset of a new pharmaco-therapeutic class?].

Chosidow O, Cribier B, Aractingi S. Chosidow O, et al. Among authors: aractingi s. Ann Dermatol Venereol. 2003 Aug-Sep;130(8-9 Pt 1):713-7. Ann Dermatol Venereol. 2003. PMID: 14576599 Review. French. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

344 results

Search Page